

Figure 1




Figure 2A




Figure 2B

Activity of TriTACs in
prostate cancer model 22Rv1





Figure 2C

EC50 [pM]	LNCaP	22Rv1
TriTAC CD3 high aff. – C324	10	35
TriTAC CD3 med. aff. – C339	87	561
TriTAC CD3 low aff. - C325	1,389	7,460

Figure 3


Serum levels of PSMA targeting TrITAC C236
in cynomolgus monkeys (0.1 mg/kg dose)



Dose Level	Animal ID	No points lambda_z	Terminal t1/2 (hr)	Cmax (ng/mL)	C0 (ng/mL)	AUC, 0-last (hr*ng/mL)	AUC, 0-inf (hr*ng/mL)	AUC %Extrapolated (%)	Clearance (mL/hr/kg)	Vss (L/kg)
0.1 mg/kg	63	6	91.6	245	253	10100	10300	1.8	9.68	1.15
	64	6	93.7	287	298	17500	17800	1.7	5.61	0.71
	Mean	6	92.6	266	276	13800	14100	1.8	7.64	0.93

Figure 4

Serum levels of PSMA targeting TriTACs in cynomolgus monkeys (0.1 mg/kg dose)



Dose Level	Animal ID	# points	Terminal t _{1/2} (hr)	C _{max} (ng/mL)	C ₀ (ng/mL)	AUC, 0-last (hr*ng/mL)	AUC, 0-inf (hr*ng/mL)	AUC % Extrapolated (%)	Clearance (mL/hr/kg)	V _{ss} (L/kg)
C324 0.1 mg/kg	2389M	5	70.3	1360	1390	47800	48100	0.568	2.08	0.192
	71F	5	101	918	941	56100	57500	2.46	1.74	0.244
	Mean	5	85.8	1140	1170	51900	52800	1.52	1.91	0.218
C339 0.1 mg/kg	2390M	6	85.3	497	533	17800	18100	1.79	5.53	0.530
	70F	6	86.5	456	523	15600	16000	2.32	6.25	0.621
	Mean	6	85.9	477	528	16700	17000	2.05	5.89	0.575

Figure 5A


Activity of TriTACs in
LNCaP model

Figure 5B





Figure 5C

EC50 [pM]	LNCaP	LNCaP with HSA	HSA shift
PSMA p8 TriTAC C362	20	43	2x
PSMA HDS TriTAC C363	10	21	2x
PSMA HTS TriTAC C364	1.3	1.3	1x
PSMA BiTE	20	9	0.5x

Figure 6



- * 22Rv1 human prostate cancer xenograft study in NOD/SCID/gamma mice reconstituted with resting, primary human T cells mixed at 1:1 ratio with cancer cells

Figure 7A

Cell line	EGFR expression	PSMA expression
LNCaP	Positive	Positive
KMS12BM	Negative	Negative
OVCAR8	Positive	Negative

Figure 7B

TDCC assay with PSMA positive LNCaP tumor cells




Figure 7C

TDCC assay with PSMA negative KMS12BM tumor cells




Figure 7D

TDCC Assay with PSMA negative OVCAR8 Cell Line




Figure 8A




Figure 8B




Figure 8C




Figure 8D




Figure 9A




Figure 9B




Figure 10




Figure 11




Figure 12

